Expert Insight Into:
Prevalence of Chronic Hepatitis B Among Foreign-Born Persons Living in the United States by Country of Origin (Part 1 of Series)
Faculty: Kris V. Kowdley, MD
Medical Writer: Lourdes Yun, MD, MSPH
Faculty: Kris V. Kowdley, MD
Medical Writer: Lourdes Yun, MD, MSPH
Click here to view our current activities in Gastroenterology.
With the ongoing migration of individuals from high and intermediate chronic hepatitis B (CHB) endemicity regions to the United States, an accurate prevalence of the disease needs to be determined so that screening, monitoring, and treatment are promptly instituted. Previous CHB prevalence studies among foreign-born persons failed to include the undocumented as well as high-risk populations. In this systematic review, Dr. Kowdley and colleagues used an innovative approach to calculate CHB prevalence by including seroprevalence studies of foreign-born persons living in the United States and in their countries of origin, and, thus, avoided sampling bias.
Kris V. Kowdley, MD
- Director, Liver Center of Excellence
- Director of Research
- Digestive Disease Institute
- Virginia Mason Medical Center
- Seattle, Washington
Robert G. Gish, MD, has received grant/research support through an institutional fund under contract to the University of California San Diego research program from Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer/Onyx, Bristol-Myers Squibb, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, Merck & Co, Inc, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; is a consultant for Abbott Laboratories, Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, HepaHope, Inc, Kadmon Corporation, LLC, Merck & Co, Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Schering-Plough Corporation, and VitalTherapies [funds directed to a UCSD SPF fund for research and education]; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche, Ltd, Merck & Co, Inc/Schering-Plough Corporation, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, and Three Rivers Pharmaceuticals [funds, except for Merck and Vertex, directed to a UCSD SPF fund for research and education]; is a major stock shareholder of HepaHope, Inc, and a minor stock shareholder of Kinex Pharmaceuticals.
Kris V. Kowdley, MD, has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Helen S. Te, MD, has disclosed no significant relationships.
Available for CME/CE:
Physicians
Publish Date: Apr 18, 2012 Termination Date: Apr 17, 2013Nurses
Publish Date: Apr 18, 2012 Termination Date: Apr 17, 2013Pharmacists
Publish Date: Apr 18, 2012 Termination Date: Dec 31, 2012Estimated time for completion of this activity:
CNE: 37.80 minutes
Target Audience
This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, nurse practitioners, nurses, physician assistants, and pharmacists who specialize in and care for patients with HBV.
Activity Goal
The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.
Learning Objective (s)
- Utilize new data on the prevalence of chronic hepatitis B (CHB) in various countries to improve the identification of foreign-born persons in the United States at risk for CHB via HBsAg serologic testing.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each of the three article reviews within this activity is worth 0.75 AMA PRA Category 1 Credits™.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.63 nursing contact hour(s).
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Kris V. Kowdley, MD has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lourdes Yun, MD, MSPH Medical Writer, has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Tibotec Pharmaceuticals, Ltd, Transgene Biotek Ltd, and Vertex Pharmaceuticals Inc; is a consultant for and/or on the advisory board of Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffmann-La Roche, Ltd, Merck & Co., Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, Tibotec Pharmaceuticals, Ltd, and Vertex Pharmaceuticals Incorporated; and is a member of the data safety monitoring boards of Anadys Pharmaceuticals, Inc, and Bayer AG
Robert G. Gish, MD has received grant/research support through an institutional fund under contract to the University of California San Diego research program from Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer/Onyx, Bristol-Myers Squibb, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, Merck & Co, Inc, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; is a consultant for Abbott Laboratories, Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, HepaHope, Inc, Kadmon Corporation, LLC, Merck & Co, Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Schering-Plough Corporation, and VitalTherapies [funds directed to a UCSD SPF fund for research and education]; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche, Ltd, Merck & Co, Inc/Schering-Plough Corporation, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, and Three Rivers Pharmaceuticals [funds, except for Merck and Vertex, directed to a UCSD SPF fund for research and education]; is a major stock shareholder of HepaHope, Inc, and a minor stock shareholder of Kinex Pharmaceuticals.
Kris V. Kowdley, MD has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Helen S. Te, MD has disclosed no significant relationships.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Apr 18, 2012 Termination Date: Apr 17, 2013Nurses
Publish Date: Apr 18, 2012 Termination Date: Apr 17, 2013Pharmacists
Publish Date: Apr 18, 2012 Termination Date: Dec 31, 2012Estimated time for completion of this activity:
CNE: 37.80 minutes
Target Audience
This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, nurse practitioners, nurses, physician assistants, and pharmacists who specialize in and care for patients with HBV.
Activity Goal
The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.
Learning Objective (s)
- Utilize new data on the prevalence of chronic hepatitis B (CHB) in various countries to improve the identification of foreign-born persons in the United States at risk for CHB via HBsAg serologic testing.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each of the three article reviews within this activity is worth 0.75 AMA PRA Category 1 Credits™.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.63 nursing contact hour(s).
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Kris V. Kowdley, MD has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lourdes Yun, MD, MSPH Medical Writer, has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Tibotec Pharmaceuticals, Ltd, Transgene Biotek Ltd, and Vertex Pharmaceuticals Inc; is a consultant for and/or on the advisory board of Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffmann-La Roche, Ltd, Merck & Co., Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, Tibotec Pharmaceuticals, Ltd, and Vertex Pharmaceuticals Incorporated; and is a member of the data safety monitoring boards of Anadys Pharmaceuticals, Inc, and Bayer AG
Robert G. Gish, MD has received grant/research support through an institutional fund under contract to the University of California San Diego research program from Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer/Onyx, Bristol-Myers Squibb, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, Merck & Co, Inc, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; is a consultant for Abbott Laboratories, Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, HepaHope, Inc, Kadmon Corporation, LLC, Merck & Co, Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Schering-Plough Corporation, and VitalTherapies [funds directed to a UCSD SPF fund for research and education]; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche, Ltd, Merck & Co, Inc/Schering-Plough Corporation, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, and Three Rivers Pharmaceuticals [funds, except for Merck and Vertex, directed to a UCSD SPF fund for research and education]; is a major stock shareholder of HepaHope, Inc, and a minor stock shareholder of Kinex Pharmaceuticals.
Kris V. Kowdley, MD has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.
Helen S. Te, MD has disclosed no significant relationships.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



